Edesa Biotech shares are trading higher after the company reported it entered into an exclusive license agreement with Novimmune and obtained exclusive rights to certain know-how, patents and data relating to monoclonal antibodies targeting TLR4 & CXCL10.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!